{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"second_quarter\", filing_year = 2022 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[2813458, "ecea9005-868b-4412-9304-8334243b5138", "Q2", "STONINGTON GLOBAL", 401105189, "SORRENTO THERAPEUTICS, INC.", 2022, "second_quarter", "PHA", "Regulatory approvals and funding for pharmaceutical products and devices", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 150000, null, 0, 0, "2022-06-20T16:50:45-04:00"], [2814122, "f66462b4-f57f-468a-8441-8ef951deb2eb", "Q2", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2022, "second_quarter", "PHA", "S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain. S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work. S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule. S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans. Issues and legislative vehicles related to capping the price of Insulin. Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR). H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2022-07-02T15:46:48-04:00"], [2814172, "676b3b06-dc3e-4649-aaf5-a25bb1476458", "Q2", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2022, "second_quarter", "PHA", "S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-04T13:37:15-04:00"], [2814452, "40fd2191-aab8-4c1a-b1f4-a376abd6b91e", "Q2", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2022, "second_quarter", "PHA", "IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 30000, 0, 0, "2022-07-05T13:49:27-04:00"], [2814491, "9d2c0b11-4fb8-45e8-8571-e94690365c12", "Q2", "FROST BROWN TODD LLC", 283572, "DISPOSERX", 2022, "second_quarter", "PHA", "H.R.7667; Issues concerning at home disposal of excess opioids as an option for pharmacies and patients", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-05T15:04:03-04:00"], [2814496, "be13b44f-4321-4a46-b608-a8f1c9055a7d", "Q2", "4C COMMUNICATIONS, INC.", 323717, "HEALTHCARE LEADERSHIP COUNCIL", 2022, "second_quarter", "PHA", "False Claims Act, COVID-19 Response, Vaccine Execution", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-05T15:10:14-04:00"], [2814647, "b1599788-aa86-4966-8b2b-21786f53e3fb", "Q2", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2022, "second_quarter", "PHA", "Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.", "HOUSE OF REPRESENTATIVES,SENATE", null, 144981, 0, 0, "2022-07-06T05:17:58-04:00"], [2815111, "12481478-6c02-4d48-abe2-5abb749ed288", "Q2", "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 401103605, "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 2022, "second_quarter", "PHA", "COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language", "HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2022-07-07T11:05:56-04:00"], [2815217, "fbb2f11d-4ce2-4f40-9de8-ba6b5e950c8b", "Q2", "ACG ADVOCACY", 2057, "WALGREEN CO.", 2022, "second_quarter", "PHA", "Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-07T14:28:54-04:00"], [2815334, "62bdcd24-6b08-498d-9069-f034d8c4b9d9", "Q2", "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 35968, "SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING", 2022, "second_quarter", "PHA", "Compounding, preparation, packaging and dispensing of radiopharmaceuticals", "Food & Drug Administration (FDA)", null, 60000, 0, 0, "2022-07-07T17:13:01-04:00"], [2815593, "2f46634f-6bb8-47df-b1bc-fad0fc85aa2e", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CVS HEALTH", 2022, "second_quarter", "PHA", "General education about the pharmacy benefit manager/pharmacy and insurance industry. Issues related to drug pricing. Issues related to the drug supply chain. Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution. Issues related to the Fiscal Year 2022 budget reconciliation process focusing on drug pricing, including H.R. 5376, the Build Back Better Act. Issues related to pharmacy provider status, including H.R. 7213, the Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-08T11:49:25-04:00"], [2815653, "9b7dc5f7-9a93-465c-b7ee-50175462274e", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "GLENMARK PHARMACEUTICALS, INC., USA", 2022, "second_quarter", "PHA", "Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-08T12:35:09-04:00"], [2815880, "f3514d38-4ef2-457f-81a2-a3c3edb2b840", "Q2", "DAVE KOLBE CONSULTING", 401104329, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2022, "second_quarter", "PHA", "Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-09T08:49:38-04:00"], [2816092, "fe037c27-1421-42b8-9a7d-b9e25888443c", "Q2", "HEALTHSPERIEN", 401103150, "EXACT CARE PHARMACY", 2022, "second_quarter", "PHA", "o Advocate for codifying definition for long-term care pharmacy. (S. 1574) o Advocate for inclusion of chronic care pharmacy in CMMI model demonstration programs", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 15000, null, 0, 0, "2022-07-10T16:23:46-04:00"], [2816127, "b26f5695-3afd-4b97-964e-d9a564ee1032", "Q2", "PENN AVENUE PARTNERS", 400918672, "ALKERMES, INC.", 2022, "second_quarter", "PHA", "Regulatory and legislative issues impacting Alkermes. S.3593 - Telehealth Extension and Evaluation Act.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-10T20:03:15-04:00"], [2816707, "cddf56b6-3b90-48e3-b3b1-ffd974da3115", "Q2", "BROWN & FORTUNATO, P.C.", 401104878, "PROMPTCARE COMPANIES, INC.", 2022, "second_quarter", "PHA", "Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators.", "Centers For Medicare and Medicaid Services (CMS)", 20000, null, 0, 0, "2022-07-11T18:23:46-04:00"], [2817211, "cf119f4e-0451-4017-be85-72e11eb5f707", "Q2", "TRINITY HEALTH", 24910, "TRINITY HEALTH", 2022, "second_quarter", "PHA", "HR 7213 To provide pharmacy reimbursement for COVID-19-related and future emergency services", "HOUSE OF REPRESENTATIVES", null, 200000, 0, 0, "2022-07-12T13:52:54-04:00"], [2817353, "fc0f5d4b-6428-41e7-b0c2-5f009724065c", "Q2", "MLJ STRATEGIES", 401105126, "ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS", 2022, "second_quarter", "PHA", "Advocating on issues related to pharmaceutical appropriations", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-12T15:07:59-04:00"], [2817359, "40de16fa-30d4-4a80-992b-4f05717ffd44", "Q2", "MLJ STRATEGIES", 401105126, "ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH", 2022, "second_quarter", "PHA", "Advocate on issues related to supplement use in the military", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-12T15:10:47-04:00"], [2817408, "4116df36-40b4-4c29-9917-e6798ecf7d6f", "Q2", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2022, "second_quarter", "PHA", "H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services.", "HOUSE OF REPRESENTATIVES,SENATE", null, 35000, 0, 0, "2022-07-12T15:45:48-04:00"], [2817568, "7ce445aa-1cb7-4d52-8c5c-984ff47ccb2c", "Q2", "MCDERMOTT+ LLC", 401103287, "ALLIANCE FOR RURAL HOSPITAL ACCESS", 2022, "second_quarter", "PHA", "Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853).", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-12T17:03:58-04:00"], [2817865, "576e40ee-3bb3-4f12-98d0-e210eff9714c", "Q2", "BROYDRICK & ASSOCIATES", 7268, "TONIX PHARMACEUTICALS", 2022, "second_quarter", "PHA", "Funding new drug for PTSD and COVID 19.", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2022-07-13T10:20:57-04:00"], [2817896, "dc7c6776-315c-4fca-8ee1-ad07ded941fb", "Q2", "HOLLAND & KNIGHT LLP", 18466, "VIATRIS INC", 2022, "second_quarter", "PHA", "Drug shortages, formulary tiering, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 (H.R. 2846), biosimilar uptake, Medicare generics penalty, generic drugs issues, supply chain issues, e-labeling provision in the FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill (H.R. 4356), and Military Construction, Veterans Affairs, and Related Agencies appropriations bill (H.R. 4355), Prescription Drug Pricing Dashboard Act (S. 1773); drug pricing; Build Back Better Act (H.R. 5376); Enhanced Access to Affordable Medicines Act of 2022 (H.R. 6973); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Generic Drug User Fee Amendments.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-13T10:48:43-04:00"], [2818409, "f21cd584-80ff-436a-bf3c-eec93b7a10f8", "Q2", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2022, "second_quarter", "PHA", "OTC switch process -- no bill number H.R. 6000 - 21st Century Cures 2.0 S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 H.R. 7667 - Food and Drug Amendments of 2022 Dietary Supplement Reform -- no bill number Cosmetics Reform -- no bill number S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022 Genus vs. FDA Circuit Court Lobby Activity", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 160270, 0, 0, "2022-07-13T16:20:50-04:00"], [2818460, "de8c62dd-c4cb-4dde-a8fb-517d106ef286", "Q2", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2022, "second_quarter", "PHA", "Issues affecting the 340B drug pricing program; Appropriations for 340B program.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2022-07-13T16:40:02-04:00"], [2818593, "700bf9e7-7990-409d-9bef-e8f341f1c15f", "Q2", "WATKINS & EAGER PLLC", 401104403, "ZYNERBA PHARMACEUTICALS, INC.", 2022, "second_quarter", "PHA", "Providing services on behalf of Zynerba to the pharmaceutical industry - looking for testing sites", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2022-07-13T20:29:39-04:00"], [2818709, "37da72f4-cd9c-4d05-945e-38e45f4c6b01", "Q2", "CONNECT 4 STRATEGIES, LLC", 401103720, "OREXO US, INC.", 2022, "second_quarter", "PHA", "Legislative and regulatory issues pertaining to Orexo Access to treatment for SUD/OUD/MAT", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-14T10:08:20-04:00"], [2818754, "bc10c58c-3d0b-40e2-862f-df02158d7273", "Q2", "LUNGREN LOPINA LLC", 401103314, "AMPAC FINE CHEMICALS", 2022, "second_quarter", "PHA", "Fair treatment for US based pharmaceutical ingredients", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2022-07-14T10:47:06-04:00"], [2818955, "eb6dffce-f163-4764-aa49-4cadf14c250c", "Q2", "PANNONE LOPES DEVEREAUX & O'GARA LLC", 401105501, "AMGEN", 2022, "second_quarter", "PHA", "Prescription drug pricing.", null, 9000, null, 0, 0, "2022-07-14T12:55:29-04:00"], [2819145, "5fea5eee-7021-417f-8dc5-55fd956d1ed6", "Q2", "RAY ANDERSON", 401105487, "340B HEALTH", 2022, "second_quarter", "PHA", "Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to eligible hospitals Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA)", 15000, null, 0, 0, "2022-07-14T14:18:58-04:00"], [2819165, "f7f4362f-9174-49ad-84b5-97393936c8ff", "Q2", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2022, "second_quarter", "PHA", "HR 4502-(fy2022 Consolidated Appropriations Act), Covid-19 Vaccine manufacturing, delivery and access and related funding, S 3799 Prevent Pandemics Act (R&D Access conditions, Public MCM manufacturing, Discounted drugs for clinical Trials Act, Pharmaceutical Research and Transparency Act, Generic Substitution Non-Interference Act, drug pricing, FDA-PTO coordination, orange book reform, NDAA licensing access and drug pricing conditions, S 3700-Affordable Insulin Now Act, Drug pricing patent licensing executive Action, Compulsory licensing to lower drug prices, HR 4521-COMPETES Act mandatory drug recall authority provision, HR 7667/ S 4348-User fee legislation, advisory committee and recall provisions, NIH Director position,", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 110000, 0, 0, "2022-07-14T14:21:58-04:00"], [2819246, "f0f621c3-7532-4264-a92d-e5f40ff50dcd", "Q2", "PARDES BIOSCIENCES, INC.", 401106493, "PARDES BIOSCIENCES, INC.", 2022, "second_quarter", "PHA", "Covid Oral Anti Virals", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE", null, 120000, 0, 0, "2022-07-14T14:54:50-04:00"], [2819789, "c10c8a18-c4ba-4891-839d-a6f0a2cec437", "Q2", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T00:33:58-04:00"], [2819795, "9af5225f-3314-47dc-8f4b-6e5edb9d6c74", "Q2", "MARSHALL & POPP, LLC", 401105121, "BUTTERFLY NETWORK, INC.", 2022, "second_quarter", "PHA", "Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T00:38:34-04:00"], [2819799, "6702f07a-360d-4b9a-85ff-00afa5e530c4", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T00:51:16-04:00"], [2820001, "b63ccaea-997c-4553-9a66-67110bd9ce2c", "Q2", "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 27478, "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 2022, "second_quarter", "PHA", "S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services", "Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 460000, 0, 0, "2022-07-15T09:57:02-04:00"], [2820215, "c483bbb7-7867-4fee-97fa-d033e4561263", "Q2", "BLUESTONE STRATEGIES, LLC", 400658980, "AMERICA'S HEALTH INSURANCE PLANS (AHIP)", 2022, "second_quarter", "PHA", "HR 3, Lower Drug Costs Now Act; HR 5260, Reduced Cost and Continued Care Act; Specialty Drugs and Prescription Drug Pricing, HR 19.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T11:15:53-04:00"], [2820234, "11b91b56-f183-409c-a151-ef5db0684aac", "Q2", "BLUESTONE STRATEGIES, LLC", 400658980, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2022, "second_quarter", "PHA", "Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T11:21:06-04:00"], [2820513, "26cd3817-2949-4029-b9d4-3e953f12c310", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)", 2022, "second_quarter", "PHA", "Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T13:01:25-04:00"], [2820578, "08120c7c-1b48-4cfc-bbde-7849afabd7a2", "Q2", "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 401104060, "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 2022, "second_quarter", "PHA", "General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 61153, 0, 0, "2022-07-15T13:25:25-04:00"], [2820708, "3228b725-e8bd-494c-a4e0-e2eb7a2d0833", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "HEMOPHILIA OF GEORGIA", 2022, "second_quarter", "PHA", "340B Drug Pricing Program, patient co-pay policies", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2022-07-15T14:37:51-04:00"], [2821155, "7fa2c441-fb2c-459c-922f-662cb9edcbbe", "Q2", "ASCENSION HEALTH ALLIANCE D/B/A ASCENSION", 401105339, "ASCENSION HEALTH ALLIANCE D/B/A ASCENSION", 2022, "second_quarter", "PHA", "340B Drug Pricing Program; Issues related to 340B contract pharmacies; Financial support for providers for diagnosis and treatment related to COVID-19, including funding for the Provider Relief Fund; coverage of COVID-19 related conditions; S. 168/H.R. 708 - Temporary; Reciprocity to Ensure Access to Treatment (TREAT) Act; S. 346/H.R. 959 - Black Maternal Health Momnibus Act; S. 773/H.R. 3203 - Legislation related to 340B eligibility; S. 368/H.R. 1332 - Telehealth Modernization Act; S. 1512/H.R. 2903 - CONNECT for Health Act; S. 1988 -Protecting Rural Telehealth Access Act; H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; S.773/H.R. 3203 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program; - S.773/H.R. 3203; H.R. 5376 - Build Back Better Act; H.R. 853 - Closing Loopholes for Orphan Drugs Act; H.R. 2471 - Consolidated Appropriations Act (FY 2022 Omnibus); H.R. 7007 - Covid-19 Supplemental Appropriations Act", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 250000, 0, 0, "2022-07-15T17:06:12-04:00"], [2821552, "193466ad-99bc-4677-b6eb-e7b47058f3db", "Q2", "REPUBLIC CONSULTING, LLC", 401016871, "IQVIA", 2022, "second_quarter", "PHA", "Monitored Health Data Policy.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-16T09:05:36-04:00"], [2821626, "396f1e9f-c53f-4881-a279-eb894395f2de", "Q2", "FORBES-TATE", 400976792, "CALIFORNIA LIFE SCIENCES ASSOCIATION", 2022, "second_quarter", "PHA", "Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2022-07-16T11:06:38-04:00"], [2822002, "5f5e34f5-1b35-453d-9697-cfb31d1d2c45", "Q2", "TREMONT STRATEGIES GROUP LLC (F/K/A ADS VENTURES)", 90250, "AMAG PHARMACEUTICAL", 2022, "second_quarter", "PHA", "Pharmaceutical issues; access to women's health pharmaceutical products.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2022-07-16T17:19:38-04:00"], [2822038, "45c61c39-a8c2-4cf4-858f-cca3e1e2cbeb", "Q2", "PENN AVENUE PARTNERS", 400918672, "UNITEDHEALTH GROUP, INC.", 2022, "second_quarter", "PHA", "Pharmacy benefit related issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office", 90000, null, 0, 0, "2022-07-16T18:28:45-04:00"], [2822104, "28192c5a-d3c2-4d06-9abe-944bab1a0337", "Q2", "FORBES-TATE", 400976792, "INDEPENDENT PHARMACY COOPERATIVE", 2022, "second_quarter", "PHA", "Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-16T19:44:37-04:00"], [2822264, "7b1ad209-0240-45e8-802f-fac6bde20456", "Q2", "MARSHALL & POPP, LLC", 401105121, "PFIZER, INC.", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-17T08:26:01-04:00"], [2822269, "fffbf069-66e0-4830-9119-2c95039df101", "Q2", "MARSHALL & POPP, LLC", 401105121, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2022-07-17T08:32:03-04:00"], [2822273, "7ea0bff6-25fe-45b6-9a7d-aecb11b1b3fc", "Q2", "MARSHALL & POPP, LLC", 401105121, "SANOFI U.S. SERVICES, INC.", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-17T08:38:32-04:00"], [2822551, "b416d924-cc4d-4cae-9694-5a3931d19d75", "Q2", "FORBES-TATE", 400976792, "PHRMA", 2022, "second_quarter", "PHA", "Issues pertaining to prescription drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-17T14:16:53-04:00"], [2822646, "25e0bdcf-0ec2-43b6-80db-906bb50a7018", "Q2", "CAPITOL COUNSEL LLC", 313715, "EMD SERONO, INC.", 2022, "second_quarter", "PHA", "Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-17T16:26:28-04:00"], [2822658, "56c25589-cbd2-4f35-ba36-c041511b644d", "Q2", "CAPITOL COUNSEL LLC", 313715, "VERTEX PHARMACEUTICALS INCORPORATED", 2022, "second_quarter", "PHA", "Monitoring and advocacy on matters related to the pharmaceutical industry.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-17T16:42:04-04:00"], [2822965, "31b95f88-9259-47dd-b366-be75e534816d", "Q2", "CORNERSTONE GOVERNMENT AFFAIRS, INC.", 75557, "CHILDREN'S NATIONAL MEDICAL CENTER", 2022, "second_quarter", "PHA", "Representation on health-related issues including reimbursement, research, public-health & clinical care", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 50000, null, 0, 0, "2022-07-17T22:39:24-04:00"], [2823610, "9c5efdb3-743c-4364-8d0c-37dbcf8702d9", "Q2", "FLYNN & ASSOCIATES, INC.", 15020, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2022, "second_quarter", "PHA", "Price controls for prescription drugs. Importation of drugs from other countries. Prescription Drug User Fee Act (reauthorization).", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-18T11:40:39-04:00"], [2824093, "24b28cce-5ab1-40af-9b18-3ddb667ceea4", "Q2", "TWENTY-FIRST CENTURY GROUP, INC.", 38687, "CARDINAL HEALTH, INC.", 2022, "second_quarter", "PHA", "Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain.", "HOUSE OF REPRESENTATIVES,SENATE", 24000, null, 0, 0, "2022-07-18T12:57:44-04:00"], [2824172, "394e059f-29b3-41be-a90c-afcadef72fa1", "Q2", "CARD & ASSOCIATES, LLC", 84217, "AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY)", 2022, "second_quarter", "PHA", "Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitoring federal appropriations for FY 2022 Access to telemedicine", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-18T13:11:03-04:00"], [2824310, "161ace94-c756-40ab-af67-723a292d99c0", "Q2", "POLSINELLI PC", 314911, "TEVA PHARMACEUTICALS USA, INC.", 2022, "second_quarter", "PHA", "Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-18T13:34:31-04:00"], [2824319, "f42a7c2c-4561-4817-9b66-9ba715c06702", "Q2", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2022, "second_quarter", "PHA", "Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances Prescription Mandate legislation Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 260000, null, 0, 0, "2022-07-18T13:36:53-04:00"], [2824418, "dd391673-662b-40d3-a3d3-9255df8906c0", "Q2", "RICCHETTI INCORPORATED", 62778, "EISAI, INC.", 2022, "second_quarter", "PHA", "Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-18T13:55:23-04:00"], [2824450, "e2b113aa-7773-4180-9800-b8a3811ba3c1", "Q2", "RICCHETTI INCORPORATED", 62778, "HORIZON THERAPEUTICS USA INC", 2022, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally Issues related to drug pricing and access, and Medicare and Medicaid reimbursement", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-18T14:00:28-04:00"], [2824527, "388f4952-ec6e-4fc1-be5d-fd3da4fe9d44", "Q2", "RICCHETTI INCORPORATED", 62778, "IPSEN BIOPHARMACEUTICALS, INC.", 2022, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)", "HOUSE OF REPRESENTATIVES", 20000, null, 0, 0, "2022-07-18T14:09:37-04:00"], [2824559, "b0ffeaa9-e4dc-4860-a099-8aaf83936f10", "Q2", "RICCHETTI INCORPORATED", 62778, "NEUROCRINE BIOSCIENCES, INC.", 2022, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2022-07-18T14:14:23-04:00"], [2824571, "ec919991-0677-4c9a-8e89-369fbe12867d", "Q2", "RICCHETTI INCORPORATED", 62778, "PARDES BIOSCIENCES, INC.", 2022, "second_quarter", "PHA", "Issues related to government involvement in the development of COVID-10 therapies", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-18T14:16:00-04:00"], [2824625, "dd2d3682-a0e3-4555-867c-5a9633c77136", "Q2", "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 3457, "AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS", 2022, "second_quarter", "PHA", "Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.", "Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 528641, 0, 0, "2022-07-18T14:23:24-04:00"], [2824680, "3579d951-469a-46f1-b516-1f7eacc233e9", "Q2", "FAEGRE DRINKER BIDDLE & REATH LLP", 12631, "ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL)", 2022, "second_quarter", "PHA", "Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; STOP Act implementation; S. 1843, H.R. 3429 - SHOP SAFE Act.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2022-07-18T14:29:53-04:00"], [2825473, "c25d0c6c-afb5-4784-996a-fca12423f1e0", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "HEINZ STRATEGIES LLC (ON BEHALF OF PILMA)", 2022, "second_quarter", "PHA", "Monitoring prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally", null, 20000, null, 0, 0, "2022-07-18T15:59:05-04:00"], [2825476, "66b41a83-5312-4aec-8557-e9570595a2e4", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2022, "second_quarter", "PHA", "Monitoring prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally", null, 20000, null, 0, 0, "2022-07-18T15:59:45-04:00"], [2825767, "2837cf26-2af5-44de-bfe8-9d38f6b358ec", "Q2", "SQUIRE PATTON BOGGS", 30906, "SK HYNIX AMERICA, INC.", 2022, "second_quarter", "PHA", "Monitor proposals and issues related to biopharmaceuticals.", "HOUSE OF REPRESENTATIVES,SENATE", 130000, null, 0, 0, "2022-07-18T16:47:16-04:00"], [2825792, "2e6731af-8c24-49c2-a17f-69d40304fb7c", "Q2", "FAEGRE DRINKER BIDDLE & REATH LLP", 12631, "NATIONAL ASSOCIATION OF BOARDS OF PHARMACY", 2022, "second_quarter", "PHA", "Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act.", "Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE", 50000, null, 0, 0, "2022-07-18T16:50:46-04:00"], [2825859, "3ff639a5-50b7-48a6-899b-634896701271", "Q2", "340B HEALTH", 316434, "340B HEALTH", 2022, "second_quarter", "PHA", "The 340B Drug Pricing Program; H.R.4390 - PROTECT 340B Act of 2021; Labor HHS Appropriations FY 2023; HR853 Closing Loopholes for Orphan Drugs Act; S. 2837, the 340B Accountability Act of 2021", "Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 298834, 0, 0, "2022-07-18T17:07:22-04:00"], [2826061, "67527880-adc7-4d5f-a24e-eacd8f02d813", "Q2", "ALB SOLUTIONS", 401105973, "BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.", 2022, "second_quarter", "PHA", "Issues related to regulatory and legislative developments regarding biosimilars.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-18T17:47:40-04:00"], [2826142, "333e8607-ccaf-42a0-8dd2-f1c1426f0757", "Q2", "HUMANITY FORWARD", 401105867, "HUMANITY FORWARD", 2022, "second_quarter", "PHA", "Issues and legislation related to reduction of prescription medication for Americans", "HOUSE OF REPRESENTATIVES,SENATE", null, 350000, 0, 0, "2022-07-18T18:18:08-04:00"], [2826188, "09a64b11-2d75-425e-97af-9505edaebd96", "2A", "HUMANITY FORWARD", 401105867, "HUMANITY FORWARD", 2022, "second_quarter", "PHA", "Issues and legislation related to reduction of prescription medication for Americans", "HOUSE OF REPRESENTATIVES,SENATE", null, 263000, 0, 0, "2022-07-18T18:34:43-04:00"], [2826256, "e4b429b7-65db-4b00-8c72-4517c8c1ddb3", "Q2", "ARENTFOX SCHIFF LLP", 4208, "AMERICAN PHARMACY COOPERATIVE, INC.", 2022, "second_quarter", "PHA", "Prescription drug pricing generally S. 4293 (Pharmacy Benefit Manager Transparency Act of 2022), regarding prescription drug pricing", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-18T18:57:55-04:00"], [2826335, "dd556bd0-0b29-4ae4-a0d0-15bce8d00c8d", "Q2", "NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)", 28264, "NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)", 2022, "second_quarter", "PHA", "Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. User Fee Agreements. Prescription Drug User Fee Act (PDUFA) Reauthorization.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2022-07-18T19:26:39-04:00"], [2826500, "dc00256f-0827-4048-805e-d832bb40b186", "Q2", "KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS)", 401105192, "CVS HEALTH", 2022, "second_quarter", "PHA", "Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. Issues related to the continuation of prescription drug access and testing during COVID crisis. Issues related to Medicare Part D rebates.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-18T20:49:22-04:00"], [2826538, "6586afdb-6bc8-4bc9-b2ed-d062914ebdf9", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "WALGREEN CO.", 2022, "second_quarter", "PHA", "Pharmacist provider status Pharmacy benefits on military bases Issues related to COVID-19 relief Issues related to drug pricing H.R.5376 - Build Back Better Act Issues related to Infrastructure Investment and Jobs Act (PL 117-58) implementation", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-18T21:12:13-04:00"], [2826842, "3c900d28-5164-464b-8233-9d6bf0da670a", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "MEDIVANT HEALTHCARE", 2022, "second_quarter", "PHA", "Issues related to pharmaceutical manufacturing and supply", null, null, null, 0, 0, "2022-07-18T22:29:41-04:00"], [2826843, "c3b5052e-0ed4-49b4-9706-54c80b27046e", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "MEDIVANT HEALTHCARE", 2022, "second_quarter", "PHA", "Issues related to pharmaceutical manufacturing and supply", null, null, null, 0, 0, "2022-07-18T22:29:50-04:00"], [2826874, "f44663db-4e73-4148-bf8c-69f6de4d5c53", "Q2", "THE MATHIS HARPLE GROUP", 322911, "PILMA", 2022, "second_quarter", "PHA", "Price Controls, Intellectual Property Rights", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-18T22:36:49-04:00"], [2826987, "a1b7bc2a-b7fe-4d46-90ec-c7b2597861bb", "Q2", "THE MATHIS HARPLE GROUP", 322911, "PHRMA", 2022, "second_quarter", "PHA", "Price Controls, Intellectual Property Rights", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2022-07-18T23:09:31-04:00"], [2827238, "b3f19194-4458-422e-883a-5018104da55d", "Q2", "VAN SCOYOC ASSOCIATES", 39837, "ZEBRA TECHNOLOGIES CORP.", 2022, "second_quarter", "PHA", "H.R.7900, National Defense Authorization Act for Fiscal Year 2023, Temperature monitoring technology, COVID Rapid Diagnostic Test Kits S.3799, PREVENT Pandemics Act, Rapid Diagnostic Test related issues Monitor Temperature monitoring technology for COVID vaccines, Domestic and International distribution related issues", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-19T07:22:41-04:00"], [2827294, "fdff7e33-b7f3-4cec-978d-5c58fe0476e7", "Q2", "TRAVERE THERAPEUTICS", 401104190, "TRAVERE THERAPEUTICS", 2022, "second_quarter", "PHA", "H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation.", "HOUSE OF REPRESENTATIVES,SENATE", null, 290000, 0, 0, "2022-07-19T07:59:16-04:00"], [2828116, "b96a3ebf-019a-43ef-8599-ee20ee082b47", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "ACER THERAPEUTICS", 2022, "second_quarter", "PHA", "COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs; - FY22 Defense Appropriations for MCM Development", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2022-07-19T10:10:47-04:00"], [2828302, "926d02e7-d331-4d0b-934b-023c023c914d", "Q2", "BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.", 6382, "BLUE CROSS AND BLUE SHIELD OF FLORIDA INC", 2022, "second_quarter", "PHA", "COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin; Coverage of Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 160000, 0, 0, "2022-07-19T10:28:55-04:00"], [2828308, "24335d24-ce9c-463a-93bb-765fbef31670", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)", 2022, "second_quarter", "PHA", "Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to the budget reconciliation process.", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-19T10:30:22-04:00"], [2828335, "6a3fdeeb-6385-498b-bfa4-5d948204297d", "Q2", "GUIDEWELL MUTUAL HOLDING CORPORATION", 401103191, "GUIDEWELL MUTUAL HOLDING CORPORATION", 2022, "second_quarter", "PHA", "COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin; Coverage of Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, null, 0, 0, "2022-07-19T10:33:02-04:00"], [2828378, "b825d0b4-dbaa-4db9-a841-689e79e4292a", "Q2", "UC HEALTH", 401103195, "UC HEALTH", 2022, "second_quarter", "PHA", "340B, Drug Pricing Reform, PBMs", "HOUSE OF REPRESENTATIVES,SENATE", null, 37500, 0, 0, "2022-07-19T10:36:22-04:00"], [2828405, "f2c485f2-c4c2-43be-9af1-fcf0b6f2f9a1", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2022, "second_quarter", "PHA", "General issues related to over-the-counter pharmaceutical supply chain. Issues related to dietary supplements, including in the prescription drug user fee agreement (PDUFA) VII.", null, 50000, null, 0, 0, "2022-07-19T10:42:37-04:00"], [2828752, "dc2e9f27-b5f7-40fa-9cf3-40a1a2a8b777", "Q2", "MASSACHUSETTS MEDICAL SOCIETY", 23975, "MASSACHUSETTS MEDICAL SOCIETY", 2022, "second_quarter", "PHA", "Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2022-07-19T11:18:36-04:00"], [2828914, "0020b9ee-c729-487f-97a6-b80261c57889", "Q2", "HERITAGE ACTION FOR AMERICA", 400609853, "HERITAGE ACTION FOR AMERICA", 2022, "second_quarter", "PHA", "HR 7667 \"Food and Drug Amendments Act,\" all provisions.", "HOUSE OF REPRESENTATIVES", null, 110000, 0, 0, "2022-07-19T11:31:15-04:00"], [2829075, "793123b9-5325-413f-bbbd-7d8a5f3f70af", "Q2", "RUBICON ADVISORS, LLC", 315091, "DYNAVAX TECHNOLOGIES", 2022, "second_quarter", "PHA", "Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA)", "HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS)", 75000, null, 0, 0, "2022-07-19T11:43:43-04:00"], [2829102, "c1390bb2-24d0-4414-a3b2-6087314d6461", "Q2", "RUBICON ADVISORS, LLC", 315091, "DR. REDDY'S LABORATORIES, LTD", 2022, "second_quarter", "PHA", "Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 60000, null, 0, 0, "2022-07-19T11:45:44-04:00"], [2829111, "19447641-2da9-4fa0-846b-27e2b43495b5", "Q2", "RUBICON ADVISORS, LLC", 315091, "CONSCIOUS DISCIPLINE", 2022, "second_quarter", "PHA", "Medicare", "HOUSE OF REPRESENTATIVES,SENATE", 67500, null, 0, 0, "2022-07-19T11:46:57-04:00"], [2829130, "598f6eea-2507-4bb4-af66-ef610d52ba05", "Q2", "RUBICON ADVISORS, LLC", 315091, "LANNETT COMPANY, INC", 2022, "second_quarter", "PHA", "Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)", 50834, null, 0, 0, "2022-07-19T11:49:14-04:00"], [2829202, "9095bb9a-c10c-4905-bf18-92d036748bd2", "Q2", "OREGON HEALTH & SCIENCE UNIVERSITY", 30291, "OREGON HEALTH & SCIENCE UNIVERSITY", 2022, "second_quarter", "PHA", "Support for the 340B Drug Discount Program for safety net hospitals and enforcing the Health Resources and Services Administration's statute governing the program.", "HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2022-07-19T11:54:27-04:00"], [2829228, "f5d58a5b-2269-44e9-bafc-acd875793e27", "Q2", "RUBICON ADVISORS, LLC", 315091, "AVET PHARMACEUTICALS", 2022, "second_quarter", "PHA", "GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES", 30000, null, 0, 0, "2022-07-19T11:57:13-04:00"], [2829229, "b56fa0ba-e58b-4341-b1a5-60efab79a1e4", "Q2", "RUBICON ADVISORS, LLC", 315091, "ASCENDIS PHARMA, INC.", 2022, "second_quarter", "PHA", "Food and Drug Administration, Orphan Drugs", "Food & Drug Administration (FDA)", 60000, null, 0, 0, "2022-07-19T11:58:09-04:00"], [2829232, "da531910-2fea-40a2-81a1-ed03aa996024", "Q2", "RUBICON ADVISORS, LLC", 315091, "HYPOPARATHYROIDISM ASSOCIATION", 2022, "second_quarter", "PHA", "Rare disease issues Orphan drugs", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS)", null, null, 0, 0, "2022-07-19T11:59:14-04:00"]], "truncated": false, "filtered_table_rows_count": 297, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "second_quarter", "p1": "2022", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 297, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA", "results": [{"value": 2022, "label": 2022, "count": 297, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA", "results": [{"value": "second_quarter", "label": "second_quarter", "count": 297, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2022&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA&_facet=filing_type"}, {"name": "income_amount", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA&_facet=income_amount"}, {"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA&_facet_date=received_date"}], "next": "2022,2829232", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2022&issue_code=PHA&_next=2022%2C2829232&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2731.2276661396027, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}